Sanofi extends bid for Genzyme
French pharmaceutical giant Sanofi-Aventis said on Monday it had extended its bid for US biotechnology group Genzyme without improving the offer after an initial deadline expired.
Sanofi-aventis announced on January 24 that it has extended its tender offer for all outstanding shares of common stock of Genzyme Corporation at $69.00 per share, net to the seller in cash, without interest and less any required withholding taxes.